Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to Harrow's First Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call.
Harrow Inc. (HROW)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 12th Street Asset Management Michael O'keefe | 168,731 | $5,949,456 | +86% | 0.97% |
| 2. | FirstWave Capital Management Jonah Lupton | 143,923 | $5,074,725 | +54% | 5.39% |
| 3. | Renaissance Technologies Jim Simons | 84,579 | $2,982,256 | -20% | 0% |
| 4. | Royce & Associates Chuck Royce | 39,713 | $1,400,280 | -93% | 0.01% |
| 5. | Pale Fire Capital Dusan Senkypl, David Holy, And Jan Barta | 8,515 | $300,239 | -28% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 20,000 | $199,400.00 | 3,815,000 | 2024-04-25 | Filing | |
| $10.15 | 8,285 | $84,092.75 | 3,795,000 | 2024-04-24 | Filing | |
| $10.29 | 11,715 | $120,547.35 | 3,786,715 | 2024-04-23 | Filing | |
| $10.56 | 29,400 | $310,390.50 | 3,775,000 | 2024-04-19 | Filing | |
| $12.82 | 50,000 | $641,000.00 | 3,745,600 | 2024-03-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.67 | 4,263 | $169,122.16 | 59,428 | 2026-03-04 | Filing | |
| $39.67 | 134,000 | $5,316,061.40 | 3,622,000 | 2026-03-04 | Filing | |
| $39.15 | 1,309 | $51,250.49 | 63,691 | 2026-03-03 | Filing | |
| $39.15 | 59,000 | $2,309,991.60 | 3,756,000 | 2026-03-03 | Filing | |
| $54.18 | 5,000 | $270,900.00 | 65,000 | 2026-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,552,759 | $90,010,282 | 0% | |
| 2. | 1,403,056 | $49,471,755 | 0% | |
| 3. | 579,520 | $20,428,332 | 0% | |
| 4. | 407,896 | $14,410,983 | 1.12% | |
| 5. | 296,865 | $10,467,461 | 0% |
News See All
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript
Operator: Welcome to the Harrow Health, Inc. fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Harrow Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Penny Insight’s Substack. In this article, we will summarize the bulls’ thesis on HROW.
Hedge Fund Resource Center